Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Natera’s second quarter of 2026 results demonstrate continued growth and operational progress across its key business segments: oncology, women’s health, and organ health.</li><li>The company processed a record 1,044,000 tests during the quarter, with clinical Minimal Residual Disease (MRD) oncology tests increasing approximately 56% year-over-year to 283,000 units, including the largest sequential increase recorded at 34,000 units above the prior quarter.</li><li>These volumes contributed to approximately $753 million in revenue, representing a 38% increase compared to Q2 2025, or 40% excluding revenue true-ups.</li></ul>

Natera’s second quarter of 2026 results demonstrate continued growth and operational progress across its key business segments: oncology, women’s health, and organ health.The company processed a record 1,044,000 tests during the quarter, with clinical Minimal Residual Disease (MRD) oncology tests increasing approximately 56% year-over-year to 283,000 units, including the largest sequential increase recorded at 34,000 units above the prior quarter.These volumes contributed to approximately $753 million in revenue, representing a 38% increase compared to Q2 2025, or 40% excluding revenue true-ups.

Natera’s $100 Million Early Cancer Detection Bet Opens A Much Bigger Long-Term Market!

<ul><li>Natera reported its second quarter of 2026 results marked by record test volume, strong revenue growth, and continued progress across its key business segments: oncology, women’s health, and organ health.</li><li>The company processed approximately 1.04 million tests during the quarter, exceeding the one million mark for the second consecutive quarter and setting a new company record.</li><li>Oncology volumes saw notable expansion, with 283,000 clinical minimal residual disease (MRD) units processed, reflecting a year-over-year increase of about 56% and a sequential increase of 34,000 units from Q1, driven by regulatory approvals, guideline endorsements, and commercial team effectiveness.</li></ul>

Natera reported its second quarter of 2026 results marked by record test volume, strong revenue growth, and continued progress across its key business segments: oncology, women’s health, and organ health.The company processed approximately 1.04 million tests during the quarter, exceeding the one million mark for the second consecutive quarter and setting a new company record.Oncology volumes saw notable expansion, with 283,000 clinical minimal residual disease (MRD) units processed, reflecting a year-over-year increase of about 56% and a sequential increase of 34,000 units from Q1, driven by regulatory approvals, guideline endorsements, and commercial team effectiveness.

Natera Unlocks Broader Signatera Adoption With FDA, PMDA And NCCN Milestones!

<ul><li>Natera reported first-quarter 2026 revenues of $697 million, representing a 39% year-over-year increase and marking the first quarter with over 1 million units delivered.</li><li>This growth was driven primarily by strong performances in both women's health and oncology segments.</li><li>The company highlighted the successful launch of Fetal Focus, a single-gene non-invasive prenatal test (NIPT) powered by LinkedSNP technology, which has quickly gained traction with nearly a 200,000 annualized run rate of orders.</li></ul>

Natera reported first-quarter 2026 revenues of $697 million, representing a 39% year-over-year increase and marking the first quarter with over 1 million units delivered.This growth was driven primarily by strong performances in both women's health and oncology segments.The company highlighted the successful launch of Fetal Focus, a single-gene non-invasive prenatal test (NIPT) powered by LinkedSNP technology, which has quickly gained traction with nearly a 200,000 annualized run rate of orders.

Natera’s Unseen Growth Lever: Japan Could Open A New Signatera Chapter!

<ul><li>Natera Inc.'s recent financial results highlight significant achievements and challenges across its business segments.</li><li>The company processed approximately 924,000 tests, including a record 225,000 minimal residual disease (MRD) tests in Q4 of 2025, marking a 56% increase compared to the previous year.</li><li>This impressive volume contributed to a total revenue of $666 million for the quarter, reflecting a year-over-year growth rate of 40%.</li></ul>

Natera Inc.'s recent financial results highlight significant achievements and challenges across its business segments.The company processed approximately 924,000 tests, including a record 225,000 minimal residual disease (MRD) tests in Q4 of 2025, marking a 56% increase compared to the previous year.This impressive volume contributed to a total revenue of $666 million for the quarter, reflecting a year-over-year growth rate of 40%.

Natera Is Quietly Raising Signatera Pricing Power — Could This Hidden Catalyst Supercharge Revenue Growth?

<ul><li>Natera, Inc. has delivered robust performance for the third quarter of 2025, reflecting significant momentum and strategic advancements across its diverse product lines.</li><li>The company reported revenues of $592 million, marking a 35% increase compared to the same quarter last year.</li><li>This growth was bolstered by substantial volume increases throughout its portfolio and record expansion of the Signatera line.</li></ul>

Natera, Inc. has delivered robust performance for the third quarter of 2025, reflecting significant momentum and strategic advancements across its diverse product lines.The company reported revenues of $592 million, marking a 35% increase compared to the same quarter last year.This growth was bolstered by substantial volume increases throughout its portfolio and record expansion of the Signatera line.

Natera: Is Signatera’s Momentum About to Accelerate Again as Biomarker Laws Expand State by State?

United States

Natera, Inc. operates as a diagnostics company. The Company provides preconception and prenatal genetic testing services. Natera also offers pre-implantation genetic diagnosis, aneuploidy screening, translocation, and single gene testing services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Natera Inc (NTRA US)

Natera’s $100 Million Early Cancer Detection Bet Opens A Much Bigger Long-Term Market!

Natera’s second quarter of 2026 results demonstrate continued growth and operational progress across its key business segments: oncology, women’s...

Baptista Research

Natera Unlocks Broader Signatera Adoption With FDA, PMDA And NCCN Milestones!

Natera reported its second quarter of 2026 results marked by record test volume, strong revenue growth, and continued progress across its key...

Baptista Research

Natera’s Unseen Growth Lever: Japan Could Open A New Signatera Chapter!

Natera reported first-quarter 2026 revenues of $697 million, representing a 39% year-over-year increase and marking the first quarter with over 1...

Baptista Research

Natera Is Quietly Raising Signatera Pricing Power — Could This Hidden Catalyst Supercharge Revenue Growth?

Natera Inc.'s recent financial results highlight significant achievements and challenges across its business segments. The company processed...

Baptista Research

Natera: Is Signatera’s Momentum About to Accelerate Again as Biomarker Laws Expand State by State?

Natera, Inc. has delivered robust performance for the third quarter of 2025, reflecting significant momentum and strategic advancements across its...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)